Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Therapeutic Area

Parkinson's Disease

Therapeutic area intelligence for Parkinson's Disease with 6 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
6
Catalysts
0
Companies
0

Companies

No related entities indexed yet.

Assets

Clinical →
FDA →
Medtronic →

Recent signals(6)

ClinicalJuly 3, 2026

Study on Bottle PEP Device Effects in Parkinson's Disease Patients

A clinical trial is investigating the impact of a low-cost bottle-PEP device on expiratory muscle strength and balance in Parkinson's disease patients.

ClinicalJuly 3, 2026

Study on Automated Parameter Optimization for Adaptive DBS in Parkinson's Disease

A new clinical trial aims to optimize adaptive deep brain stimulation (aDBS) parameters for Parkinson's disease patients using an automated, data-driven approach.

RegulatoryJuly 1, 2026

FDA Grants AP Status for Carbidope and Levodopa Supplement by Rubicon Research

The FDA has granted an Abbreviated New Drug Application (ANDA) AP status for a supplement of Carbidope and Levodopa submitted by Rubicon Research.

ClinicalJune 30, 2026

Study on Vagus Nerve Stimulation in Parkinson's Disease Underway

A clinical trial is investigating the effects of transcutaneous vagus nerve stimulation on gut-brain communication in Parkinson's disease patients.

ClinicalJune 23, 2026

Trial Compares VR and Dual-Task Training for Balance in Parkinson's Disease

A clinical trial is evaluating the efficacy of cognitive-based balance rehabilitation using Virtual Reality versus traditional Dual-Task Training in Parkinson's Disease patients.

ClinicalJune 23, 2026

Clinical Trial Evaluates Adaptive DBS for Parkinson's Disease Management

A clinical trial is underway to assess the efficacy and safety of an adaptive deep brain stimulation system for Parkinson's disease.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Parkinson's Disease →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.